Skip to main content
Premium Trial:

Request an Annual Quote

IBM, Molecular Mining Sign Marketing and Research Agreement

NEW YORK, June 10-IBM and Molecular Mining Corporation will work together to develop data mining and software products that analyze gene and protein expression, predict individual drug responses, and probe the genetic causes of disease, the companies said today.


The companies will launch a joint sales and marketing effort that pairs IBM DiscoveryLink software with MMC's GeneLinker visualization and analysis systems. GeneLinker platinum will be shipped on IBM Intellistation systems, and new MMC products will be available first through IBM platforms.


Both companies will become "preferred partners" for one another.


MMC will use IBM systems for internal development, including an infrastructure cluster of Linux-based eServer xSeries systems supported by the IBM Life Sciences Framework.


IBM and MMC may also collaborate to find new methods of pattern discovery and gene expression analysis.


Financial details were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.